VistaGen FY27 Q1 net loss narrows to $13.03 million; revenue rises to $1.48 million

Reuters2026/08/14 12:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

VistaGen posted Q1 FY2027 revenue of USD 1.48 million, up from USD 244,000 a year earlier.
Net loss narrowed to USD 13.03 million from USD 15.1 million; loss per share improved to USD 0.3 from USD 0.47.
R&D costs edged down to USD 10.91 million from USD 11.68 million; G&A expense fell to USD 3.92 million from USD 4.37 million.
Cash, cash equivalents, and marketable securities totaled USD 31.7 million at June 30, 2026; runway expected into 2027.
FDA engagement planned this quarter on a potential Phase 3 path for fasedienol after PALISADE-4 missed its primary endpoint overall.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608140832PRIMZONEFULLFEED9810348) on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

VistaGen FY27 Q1 net loss narrows to $13.03 million; revenue rises to $1.48 million

You may also like

Crypto prices